Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results

Martin Gutierrez, Wei‐Sen Lam, Matthew D. Hellmann, Matthew A. Gubens, Charų C. Aggarwal, Daniel S.W. Tan, Enriqueta Felip, Joanne Chiu, Jong-Seok Lee, James C. Yang, Edward B. Garon, Giovanna Finocchiaro, Myung‐Ju Ahn, Alexander Luft, Gregory Landers, Andrea Basso, Hua Ma, Julie Kobie, John Palcza, Răzvan Cristescu, Lawrence Fong, Alexandra Snyder, Jianda Yuan, Roy S. Herbst